|  |
| --- |
| The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the PBS or the National Immunisation Program.The PBAC agenda consists of the following:**1 Minutes of Previous Meeting****2 Chairman’s report (verbal)****3 Matters arising from the minutes****4 Matters arising/outstanding****5 New drug applications****6 Requests for changes to listings****7 Resubmissions****8 Pricing Matters****9 Matters relating to PBS review****10 Subcommittee and Working Party reports****11 Other business****12 Correspondence****13 Further information****14 Late papers****15 Tabled papers**Consumers will have the opportunity to provide comments on new drug submissions (item 5), changes to listings (item 6) and resubmissions (item 7). In many circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceutical benefits listed in the Schedule fall into three broad categories:*Unrestricted benefits* – have no restrictions on their therapeutic uses; *Restricted benefits* – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and *Authority required benefits* – Authority required benefits fall into two categories: * *Authority required benefits* require prior approval from Medicare Australia or the DVA (noted as Authority required)
* *Authority required (STREAMLINED) benefits* do not require prior approval from Medicare Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Submissions are categorised broadly as major or minor:* *Major:* Submissions to list new medicines on the Schedule of Pharmaceutical Benefits or to make substantial changes to current listings are generally classified as major submissions. Major submissions require presentation of an economic evaluation.
* *Minor:* Submissions that relate to new forms of previously listed products and changes to the conditions of use e.g. change in maximum quantity/repeats or clarifying the wording of a restriction (while not altering the intended use) are considered to be minor submissions. Minor submissions do not usually require the presentation of an economic evaluation.
 |

| **Submission type**(new listing, change to listing) | **Drug Name, form(s), strength(s) and Sponsor**(Drug name, form, strength, Trade name®, Sponsor) | **Drug Type and Use**(What is the drug used to treat?) | **Listing requested by Sponsor / Purpose of Submission**(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| --- | --- | --- | --- |
| Change to listing(Minor Submission) | 1) MEDIUM CHAIN TRIGLYCERIDES2) TRIGLYCERIDES LONG CHAIN1) Oral liquid 225 mL (betaquik)2) Oral liquid 225 mL (carbzero)1) Betaquik 2) CarbzeroVitaflo Australia Pty Ltd | 1) Ketogenic diet; dietary management of conditions requiring a source of medium chain triglycerides2) Ketogenic diet | To advise the PBAC of a change to the formulation and request a change in the pack size and maximum quantity of Betaquik and Carbzero. |
| New listing(Major Submission) | ALIROCUMABInjection 75 mg in 1 mL single dose pre-filled penInjection 150 mg in 1 mL single dose pre-filled penPraluent® Sanofi-Aventis Australia Pty Ltd | Familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease  | To request an Authority Required listing for the treatment of patients with familial heterozygous hypercholesterolaemia and clinical atherosclerotic cardiovascular disease. |
| New listing(Minor Submission) | AMINO ACID FORMULA WITH VITAMINS, MINERALS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS, WITHOUT PHENYLALANINEOral powder 400 g (PKU Start)PKU Start®Vitaflo Australia Pty Ltd | Phenylketonuria | To request a Restricted Benefit listing for the dietary management of patients with phenylketonuria. |
| New listing(Major Submission) | APREMILAST Tablet 30 mgPack containing 4 tablets of 10 mg , 4 tablets of 20 mg and 19 tablets of 30 mgOtezla®Celgene Pty Ltd | Moderate to severe plaque psoriasis | Resubmission to request a Restricted Benefit listing for treatment of patients with moderate to severe plaque psoriasis. |
| New listing(Minor Submission) | ARGININETablet 500 mgArginine Easy®Orpharma Pty Ltd | Urea cycle disorders (UCD) | To request a Restricted Benefit listing for the treatment of UCD. |
| New listing(Major Submission) | ATEZOLIZUMAB Solution concentrate for I.V. infusion 1200 mg in 20 mL Tecentriq®Roche Products Pty Ltd  | Non-small cell lung cancer (NSCLC) | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of locally advanced (stage IIIB) or metastatic (stage IV) NSCLC with progression on or after prior chemotherapy. |
| New listing(Minor Submission) | BARICITINIBTablet 2 mgTablet 4 mgOlumiant®Eli Lilly Australia Pty Ltd | Severe active rheumatoid arthritis (RA) | Resubmission to request an Authority Required listing for the treatment of severe active RA under certain conditions. |
| New listing(Major Submission) | BEZLOTOXUMAB Solution concentrate for I.V. infusion 1000 mg in 40 mL Zinplava®Merck Sharp & Dohme (Australia) Pty Ltd | Prevention of Clostridium difficile infection (CDI) recurrence  | To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing to prevent recurrence of CDI, as an add-on to antibiotic treatment. |
| Change to listing(Minor Submission)WITHDRAWN | BLINATUMOMABPowder for I.V. infusion 38.5 microgramsBlincyto®Amgen Australia Pty Ltd | Relapsed or refractory acute lymphoblastic leukemia | To request that the current Section 100 (Efficient Funding of Chemotherapy) supply arrangements be amended to Section 100 (Highly Specialised Drugs). |
| New listing(Minor Submission) | BRIVARACETAMTablet 25 mgTable 50 mg Tablet 75 mgTablet 100 mgOral suspension 10 mg per mL, 300 mLBriviact®UCB Australia Pty Ltd | Epilepsy | Resubmission to request Authority Required (STREAMLINED) listing for the treatment of intractable partial onset epileptic seizures. |
| New listing(Minor Submission) | BUDESONIDE WITH EFORMOTEROLPowder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 dosesPowder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 120 dosesDuoResp® Spiromax®Teva Pharma Australia Pty Limited | Asthma and chronic obstructive pulmonary disease (COPD)  | Resubmission to request a Restricted Benefit listing for a new brand of budesonide with eformoterol (DuoResp® Spiromax®) for the treatment of patients with asthma and COPD aged 18 years and over. |
| New listing(Major Submission) | BUDESONIDECapsule (modified release) 3 mgEntocort®Emerge Health Pty Ltd | Crohn disease  | To request an Authority Required listing for the treatment of patients with mild to moderate Crohn disease affecting the ileum and/or the ascending colon who meet certain criteria. |
| Change to recommended listing(Major Submission) | CANAKINUMABPowder for injection 150 mg with solventSolution for injection 150 mg in 1 mLIlaris®Novartis Pharmaceuticals Australia Pty Ltd | Cryopyrin associated periodic syndromes (CAPS) | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of patients with moderate to severe CAPS. |
| New listing(Major Submission) | CLADRIBINETablet 10 mgMavenclad®Merck Serono Australia Pty Ltd | Relapsing-remitting multiple sclerosis (RRMS) | Resubmission to request an Authority Required listing for the treatment of RRMS. |
| Change to listing(Major Submission) | CRIZOTINIBCapsule 200 mg Capsule 250 mgXalkori® Pfizer Australia Pty Ltd | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with a ROS1 gene rearrangement confirmed by fluorescent in situ hybridisation (FISH) testing | To request an Authority Required listing for the treatment of patients with Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC with a ROS1 gene rearrangement confirmed by FISH testing, in patients who have failed at least one treatment with platinum-based chemotherapy. |
| New listing(Minor Submission) | 1) DAPAGLIFLOZIN2) DAPAGLIFLOZIN WITH METFORMIN3) DAPAGLIFLOZIN WITH SAXAGLIPTIN1) Tablet 10 mg (as propanediol monohydrate)2) Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride3) Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 5 mg saxagliptin1) Forziga®2) Xigduo® XR3) Qtern®AstraZeneca Pty Ltd | Type 2 diabetes mellitus (T2DM) | Resubmission to request an Authority Required (STREAMLINED) listing for dapagliflozin in combination with a dipeptidyl peptidase 4 (DPP4) inhibitor and metformin for the treatment of T2DM.  |
| New listing(Major Submission) | DARATUMUMAB Solution concentrate for I.V infusion 100 mg in 5 mLSolution concentrate for I.V infusion 400 mg in 20 mLDarzalex® Janssen-Cilag Pty Ltd | Relapsed/refractory multiple myeloma | To request an Authority Required listing, in combination with bortezomib or lenalidomide, for the treatment of relapsed or refractory multiple myeloma in patients who have progressive disease after at least one prior therapy. |
| New listing(Minor Submission) | DEFERIPRONETablet 1000 mgFerriprox® Apotex Pty Ltd | Iron overload | To request an Authority Required (STREAMLINED) listing of new form of deferiprone. |
| Change to listing(Major Submission) | DEXAMETHASONE Intravitreal injection 700 microgramsOzdurex® Allergan Australia Pty Ltd | Non-infectious uveitis (inflammatorydisease of the eye) | To request an Authority Required listing for the treatment of non-infectious uveitis affecting the posterior segment of the eye. |
| New listing(Major Submission) | DULAGLUTIDEInjection 1.5 mg in 0.5 mL single dose pre-filled penTrulicity®Eli Lilly Australia Pty Ltd | Type 2 diabetes mellitus (T2DM) | To request an Authority Required (STREAMLINED) listing for use in combination with metformin or metformin and a sulfonylurea, for the treatment of T2DM. |
| New listing(Major Submission) | EMPAGLIFLOZIN WITH LINAGLIPTINTablet containing 10 mg empagliflozin with 5 mg linagliptinTablet containing 25 mg empagliflozin with 5 mg linagliptinGlyxambi®Boehringer Ingelheim Pty Limited | Type 2 diabetes mellitus (T2DM) | Resubmission to request an Authority Required (STREAMLINED) listing for use in combination with metformin for the treatment of T2DM. |
| Change to listing(Minor Submission) | 1) EMPAGLIFLOZIN2) EMPAGLIFLOZIN WITH METFORMIN3) LINAGLIPTIN4) LINAGLIPTIN WITH METFORMIN1) Tablet 10mg Tablet 25 mg2) Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride3) Tablet 5 mg4) Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride Tablet containing 2.5 mg linagliptin with 1 g metformin hydrochloride Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride1) Jardiance®2) Jardiamet® 3) Trajenta® 4) Trajentamet®Boehringer Ingelheim Pty Limited | Type 2 diabetes mellitus (T2DM) | To request an Authority Required (STREAMLINED) for the use in triple oral therapy regimen of empagliflozin and linagliptin with metformin for the treatment of T2DM. |
| Change to listing(Major Submission) | EVOLOCUMABInjection 420 mg in 3.5 mL single use pre-filled cartridgeInjection 140 mg in 1 mL single use pre-filled penRepatha® Amgen Australia Pty Ltd | Familial hypercholesterolaemia (FH)/ hypercholesterolaemia with symptomatic atherosclerotic cardiovascular disease (ASCVD) who do not have underlying FH  | Resubmission to request an Authority Required listing for treatment of patients with FH and patients with non-familial hypercholesterolaemia who have symptomatic ASCVD.  |
| New listing(Major Submission) | FOLLITROPIN DELTASolution for injection 12 micrograms per 0.36 mL pre-filled cartridgeSolution for injection 36 micrograms per 1.08 mL pre-filled cartridgeSolution for injection 72 micrograms per 2.16 mL pre-filled cartridgeRekovelle®Ferring Pharmaceuticals Pty Ltd | Assisted reproductive technology (ART) | To request a Section 100 (IVF) Authority Required (STREAMLINED) listing for controlled ovarian stimulation in ART. |
| New listing(Minor Submission) | GLECAPREVIR WITH PIBRENTASVIRTablet containing 100 mg glecaprevir with 40 mg pibrentasvirMaviret®AbbVie Pty Ltd | Chronic hepatitis C virus (HCV) infection | To request an Authority Required General Schedule and Section 100 (Highly Specialised Drug) listing for chronic HCV infection in patients who have failed prior treatment with an NS5A inhibitor. |
| New listing(Minor Submission) | GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSBars 81 g, 14 (Tylactin Complete)Tylactin Complete®Cortex Health | Tyrosinaemia | To request a Restricted Benefit Listing for the dietary management of tyrosinaemia. |
| New listing(Minor Submission) | GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSSachets containing oral powder 16 g, 60 (PKU Build 10)Sachets containing oral powder 32g, 30 (PKU Build 20)PKU Build 10®PKU Build 20®Cortex Health Pty Ltd | Phenylketonuria | To request a Restricted Benefit listing for the dietary management of phenylketonuria. |
| Change to listing(Major Submission) | GOLIMUMAB Injection 50 mg in 0.5 mL single use pre-filled syringe Simponi®Janssen-Cilag Pty Ltd | Active non-radiographic axial spondyloarthritis | To request an Authority Required listing for the treatment of active non-radiographic axial spondyloarthritis. |
| New listing(Major Submission) | GOLIMUMABInjection 100 mg in 1 mL single use pre-filled syringeSimponi®Janssen-Cilag Pty Ltd | Moderate to severe ulcerative colitis | To request an Authority Required listing for the treatment of adult patients with moderate to severe ulcerative colitis, who have had an inadequate response to conventional therapy. |
| Change to recommended listing(Major Submission) | IBRUTINIBCapsule 140 mg Imbruvica®Janssen-Cilag Pty Ltd | Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) | To request an Authority Required listing for the first line treatment of patients with CLL or SLL who meet certain criteria. |
| Change to recommended listing(Major Submission) | IBRUTINIBCapsule 140 mg Imbruvica®Janssen-Cilag Pty Ltd | Relapsed or refractory mantle cell lymphoma | Resubmission to request an Authority Required listing for the treatment of relapsed or refractory mantle cell lymphoma. |
| Change to listing(Minor Submission) | INFLIXIMABPowder for I.V. infusion 100 mgRenflexis®Merck Sharp & Dohme (Australia) Pty Ltd | Multiple indications | To request that the current listings for Renflexis be changed to Authority Required (STREAMLINED) for patients continuing on treatment or switching from the reference biologic or from another bDMARD. |
| New listing(Major Submission) | INSULIN DEGLUDEC WITH INSULIN ASPARTInjections, cartridges, 70 units-30 units per mL, 3 mL, 5Injections, pre-filled pen, 70 units-30 units per mL, 3 mL, 5Ryzodeg FlexTouch®Ryzodeg Penfill®Novo Nordisk Pharmaceuticals Pty Ltd | Diabetes mellitus | To request an unrestricted listing to improve glycaemic control in adult patients with diabetes mellitus where basal and prandial insulin treatment is necessary. |
| New listing(Minor Submission) | INSULIN LISPROInjections (human analogue), cartridges, 200 units per mL, 3 mL, 5Humalog® U200 Kwikpen® Eli Lilly Australia Pty Ltd | Diabetes mellitus | To request an unrestricted listing of a new form of insulin lispro. |
| Change to listing(Minor Submission) | LANREOTIDEInjection 60 mg (as acetate) in single dose pre-filled syringeInjection 90 mg (as acetate) in single dose pre-filled syringeInjection 120 mg (as acetate) in single dose pre-filled syringeSomatuline® Autogel®Ipsen Pty Ltd | Acromegaly and functional carcinoid tumour | To request that the current listing supply arrangements be changed from Section 100 (Highly Specialised Drugs Program) to Section 100 (Highly Specialised Drugs Program - Community Access).  |
| Change to listing(Minor Submission) | LANREOTIDEInjection 120 mg (as acetate) in single dose pre-filled syringeSomatuline® Autogel®Ipsen Pty Ltd | Non-functional gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) | Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of non-functional GEP-NETs in adult patients with un-resectable locally advanced or metastatic disease. |
| Change to listing(Major Submission) | LENVATINIB Capsule 10 mg (as mesilate)Capsule 4 mg (as mesilate)Lenvima®Eisai Australia Pty Ltd | Advanced renal cell carcinoma | To request an Authority Required (STREAMLINED) listing for the treatment of patients with advanced renal cell carcinoma following treatment with at least one anti-angiogenic therapy. |
| Change to listing(Minor Submission) | MEPOLIZUMABPowder for injection 100 mgNucala®GlaxoSmithKline Australia Pty Ltd | Uncontrolled severe eosinophilic asthma | To request an extension to the duration that eosinophil test results are considered valid to support initial access to PBS-subsidised mepolizumab. |
| New listing(Major Submission) | MIDOSTAURINCapsule 25 mgRydapt®Novartis Pharmaceuticals Australia Pty Ltd | Acute myeloid leukaemia (AML) | To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing of midostaurin for the treatment of patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3) mutation positive AML. |
| New listing(Minor Submission) | MIGALASTATCapsule containing migalastat hydrochloride 150 mgGalafold®Amicus Therapeutics | Fabry disease | Resubmission to request a Section 100 (Highly Specialised Drug) Authority Required listing for the treatment of Fabry disease. |
| Change to listing(Major Submission) | NIVOLUMAB Injection concentrate for I.V. infusion 40 mg in 4 mLInjection concentrate for I.V. infusion 100 mg in 10 mLOpdivo®Bristol-Myers Squibb Australia Pty Ltd | Squamous cell carcinoma for the head and neck (SCCHN) | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) that progresses within 6 months following platinum-based therapy.  |
| Change to listing(Major Submission)WITHDRAWN | NIVOLUMAB Injection concentrate for I.V. infusion 40 mg in 4 mLInjection concentrate for I.V. infusion 100 mg in 10 mLOpdivo® Bristol-Myers Squibb Australia Pty Ltd | Relapsed/refractory classical Hodgkin Lymphoma (CHL) | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of patients with relapsed/refractory CHL after autologous stem cell transplant and treatment with brentuximab vedotin. |
| New listing(Major Submission) | NUSINERSENSolution for injection 12 mg in 5 mL Spinraza™Biogen Australia Pty Ltd | Spinal muscular atrophy (SMA) | To request a Section 100 (High Specialised Drugs Program) Authority Required listing for treatment of patients with infantile-onset (Type I) and childhood-onset (Types II and III) SMA.  |
| Change to listing(Major Submission) | OBINUTUZUMAB Solution for I.V. infusion 1000 mg in 40 mLGazyva®Roche Products Pty Ltd  | CD20 positive follicular lymphoma | To request an Authority Required (STREAMLINED) listing for untreated patients with Stage II bulky or Stage III/IV CD20 positive follicular lymphoma. |
| Change to recommended listing(Major Submission) | OCRELIZUMAB Solution concentrate for I.V. infusion 300 mg in 10 mLOcrevus®Roche Products Pty Ltd  | Primary progressive multiple sclerosis (PPMS) | To request an Authority Required (STREAMLINED) listing for the treatment of adult patients with PPMS. |
| New listing(Major Submission) | OSIMERTINIBTablet 40 mg Tablet 80 mgTagrisso®AstraZeneca Pty Ltd | Locally advanced (Stage III) or metastatic (Stage IV) epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC) | To request an Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic EGFR T790M mutation positive NSCLC who have progressed on or after prior treatment with an EGFR tyrosine kinase inhibitor (TKI). |
| New listing(Major Submission) | PALBOCICLIBCapsule 75 mgCapsule 100 mg Capsule 125 mgIbrance® Pfizer Australia Pty Ltd | Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer | Resubmission to request an Authority Required listing as initial endocrine-based therapy in patients with HR+, HER2- locally advanced, inoperable or metastatic breast cancer in combination with a non-steroidal aromatase inhibitor. |
| Change to listing(Minor Submission) | PEGINTERFERON ALFA-2AInjection 135 micrograms in 0.5 mL single use pre filled syringeInjection 180 micrograms in 0.5 mL single use pre‑filled syringePegasys®Roche Products Pty Ltd  | Myeloproliferative neoplasms (MPN) | To request the current Section 100 (Highly Specialised Drugs) Authority Required (STREAMLINED) listing to be changed to an unrestricted listing. |
| Change to listing(Major Submission) | PEMBROLIZUMAB Powder for injection 50 mg Solution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®Merck Sharp & Dohme (Australia) Pty Ltd | Locally advanced or metastatic urothelial cancer (LA or mUC) | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of LA or mUC after the failure of a prior platinum-containing regimen. |
| Change to listing(Major Submission) | PEMBROLIZUMABPowder for injection 50 mg Solution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®Merck Sharp & Dohme (Australia) Pty Ltd | First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing as first line monotherapy in patients expressing PD-L1 for NSCLC. |
| Change to listing(Minor Submission) | POMALIDOMIDECapsule 3 mg Capsule 4 mgPomalyst®Celgene Pty Ltd | Relapsed/refractory multiple myeloma  | Resubmission to request an amendment to the S100 (Highly Specialised Drug) listing to include patients with relapsed or refractory multiple myeloma who are contraindicated or intolerant to bortezomib and/or lenalidomide. |
| Change to listing(Minor Submission) | PONATINIBTablet 15 mg (as hydrochloride)Tablet 45 mg (as hydrochloride)Inclusig®Specialised Therapeutics Australia  | Relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukaemia (ALL) | To request a change to the current Authority Required listing for the treatment of Philadelphia chromosome positive ALL to remove the requirement to have a T315I mutation. |
| New listing(Minor Submission) | PRALATREXATESolution for I.V. infusion 20 mg in 1 mLFolotyn®Mundipharma Pty Ltd | Peripheral T-Cell Lymphoma | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required listing for the treatment of patients with peripheral T-cell lymphoma who are refractory to, or have relapsed following, first line chemotherapy. |
| New listing(Minor Submission) | RADIUM (223Ra)Injection containing radium (223Ra) dichloride 6.6 MBq in 6 mL vialXofigo®Bayer Australia Ltd | Metastatic castrate resistant prostate cancer (mCRPC) | To request the Authority Required listing for the treatment of mCRPC. |
| New listing(Major Submission) | RIBOCICLIB Tablet 200 mgKisqali® Novartis Pharmaceuticals Australia Pty Ltd | Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer | Resubmission to request an Authority Required listing as initial endocrine-based therapy in patients with HR+, HER2- locally advanced, inoperable or metastatic breast cancer in combination with a non-steroidal aromatase inhibitor, who are not premenopausal. |
| New listing(Minor Submission) | SEVELAMER Powder for oral liquid 2.4 g (as carbonate)Renvela®Sanofi-Aventis Australia Pty Ltd  | Hyperphosphataemia in patients with chronic kidney disease | To request an Authority Required (STREAMLINED) listing of new form of sevelamer. |
| New listing(Major Submission) | SODIUM PHENYLBUTYRATE Granules for oral suspension 483 mg (as sodium) per g, 174 gPheburane®Orpharma Pty Ltd | Urea cycle disorder (UCD) | To request an Authority Required listing for the treatment of patients with UCD. |
| New listing(Major Submission) | SONEDIGIBCapsule 200 mgOdomzo®Sun Pharma ANZ Pty Ltd | Basal cell carcinoma (BCC) | To request an Authority Required listing for the treatment of patients with metastatic or locally advanced BCC who are not suitable to curative surgery or radiation therapy. |
| New listing(Major Submission)WITHDRAWN | STIRIPENTOLCapsule 250 mg Capsule 500 mg Sachet containing powder for oral suspension 250 mg Sachet containing powder for oral suspension 500 mgDiacomit®Emerge Health Pty Ltd | Severe myoclonic epilepsy in infancy (SMEI, also known as Dravet Syndrome)  | To request an Authority Required (STREAMLINED) listing for use in combination with sodium valproate and clobazam for the treatment of patients with SMEI (also known as Dravet Syndrome) who meet certain criteria. |
| New listing(Major Submission) | TEDUGLUTIDEPowder for injection 5 mg with solventRevestive®Shire Australia Pty Ltd | Short Bowel Syndrome (SBS) | To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing for the treatment of SBS in patients who are dependent on parenteral nutrition for survival. |
| Change to listing(Minor Submission) | TETRACOSACTRINCompound depot injection 1 mg in 1 mLSynacthen® Depot 1 mg/1 mLLink Medical Products Pty Ltd | Hypsarrhythmia and infantile spasms | To request the current unrestricted listing be changed to Restricted Benefit for the treatment of hypsarrythmia and/or infantile spasms. |
| Change to listing(Minor Submission) | TIOTROPIUMSolution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)Spiriva® Respimat®Boehringer Ingelheim Pty Ltd | Severe asthma  | Resubmission to request the current Restricted Benefit listing for severe asthma be changed to Authority Required (STREAMLINED). |
| New listing(Minor Submission) | TRIFLURIDINE WITH TIPIRACILTablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride)Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride)Lonsurf®Servier Laboratories (Australia) Pty Ltd | Metastatic colorectal cancer | Resubmission to request an Authority Required (STREAMLINED) listing for the treatment of metastatic colorectal cancer. |
| Change to listing(Minor Submission) | VARENICLINETablet 1 mg (as tartrate)Champix®Pfizer Autralia Pty Ltd | Nicotine dependence | To request amendment on the Authority Required (STREAMLINED) listing for the treatment of nicotine dependence to enable access for patients who commence treatment in hospital. |
| Change to recommended listing(Minor Submission) | VENETOCLAXTablet 10 mgTablet 50 mgTablet 100 mgVenclexta®AbbVie Pty Ltd | Relapsed/refractory chronic lymphoid leukaemia (CLL) | To request that the PBAC review the circumstances of listing recommended at its July 2017 meeting. |
| Change to listing(Major Submission) | 1. VILDAGLIPTIN2. VILDAGLIPTIN WITH METFORMIN1. Tablet 50 mg 2. Tablet containing 50 mg vilgagliptin with 500 mg metformin hydrochloride Tablet containing 50 mg vilgagliptin with 850 mg metformin hydrochloride Tablet containing 50 mg vilgagliptin with 1000 mg metformin hydrochloride1. Galvus® 2. Galvumet® Novartis Pharmaceuticals Australia Pty Ltd | Type 2 diabetes mellitus (T2DM) | To request an Authority Required (STREAMLINED) listing for use in combination with insulin for the treatment of patients with T2DM.  |
| Sub-committee report(DUSC analysis) | DUSC Analysis – 5‑aminosalicylic acid (5-ASA) utilisationBalsalazide (Colazide®, Fresenius Kabi Australia Pty Ltd)Mesalazine: (Mesasal®, Aspen Pharmaceuticals Australia Pty Ltd);(Mezavant®, Shire Australia Pty Ltd);(Pentasa®, Ferring Pharmaceuticals Pty Ltd);(Salofalk®, Orphan Australia Pty Ltd)Osalazine (Dipentum®, Clinect Pty Ltd)Sulfasalazine:(Pyralin EN®, Pfizer Australia Pty Ltd);(Salazopyrin®, Pfizer Australia Pty Ltd) | Ulcerative colitis | To report on whether the increasing utilisation of 5-aminosalicylic acid (5-ASA) medicines used to treat ulcerative colitis is due to more patients treated or higher doses. This report is in response to actions arising from the July 2017 consideration of the DUSC Ulcerative Colitis analysis.   |
| Sub-committee report(DUSC analysis) | Everolimus (Afintor®, Novartis Pharmaceuticals Australia Pty Ltd)Sunitinib (Sutent®,Pfizer Australia Pty Ltd) | Pancreatic neuroendocrine tumours | To report on the predicted versus actual use of everolimus and sunitinib to treat well-differentiated, malignant, pancreatic neuroendocrine tumours (pNET). |
| Sub-committee report(DUSC analysis) | Lenalidomide (Revlimid®, Celgene Pty Limited) | Myelodysplastic syndrome | To report on the predicted versus actual use of lenalidomide to treat myelodysplastic syndrome.  |
| Sub-committee report(DUSC analysis) | Eculizumab (Soliris®, Alexion Pharmaceuticals Australasia Pty Ltd) | Atypical haemolytic uraemic syndrome | To report on the predicted versus actual use of eculizumab to treat atypical haemolytic uraemic syndrome (aHUS). |
| Sub-committee report(DUSC analysis) | Nanoparticle albumin-bound paclitaxel (Abraxane®, Specialised Therapeutics Australia Pty Ltd) | Metastatic adenocarcinoma of the pancreas | To report on the predicted versus actual use of nanoparticle albumin-bound paclitaxel to treat metastatic adenocarcinoma of the pancreas. |
| Sub-committee report(DUSC analysis) | Bortezomib (Velcade®, Janssen-Cilag Pty Ltd); lenalidomide (Revlimid®, Celgene Pty Ltd); pomalidomide (Pomalyst®, Celgene Pty Ltd);  thalidomide (Thalomid®, Celgene Pty Ltd) | Multiple Myeloma | To report on the use of bortezomib, lenalidomide, pomalidomide and thalidomide to treat multiple myeloma; including the predicted versus actual use.  |
| Evaluation of Post market review | Salbutamol Terbutaline Ipratropium Beclomethasone Fluticasone Budesonide Ciclesonide Sodium cromoglycate Nedocromil sodium Montelukast Salmeterol Eformoterol Fluticasone with SalmeterolFluticasone with Eformoterol Fluticasone with Vilanterol Budesonide with Eformoterol Oral glucocorticoids, plain(all listed brands) | Asthma | To consider the findings from the evaluation of the 2014 Post market review of PBS medicines used to treat asthma in children. |